ARTICLE | Clinical News
TriRima: Phase II started
January 10, 2011 8:00 AM UTC
CeNeRx began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 125 mg TriRima twice daily in 360 patients. CeNeRx has rights to TriRima from Krenitsky under a 2005 deal. ...